Conjoint Analysis of French and German Parents??? Willingness to Pay for Meningococcal Vaccine

Abstract

In Germany and France, where there is still limited out-of-pocket health spending, the majority of sampled respondents stated that they would purchase meningococcal vaccines with their own money.

Pediatricians’ Preferences for Infant Meningococcal Vaccination

“…As in our study, most respondents in the Bishai et al [11] study (93%) indicated that they would purchase a vaccine if it was not free. The study results indicated that the uptake of a quadrivalent meningococcal vaccine that lasted 10 years would be 50% in France and Germany at prices of €80 and €50, respectively.…”

“…These concerns may cause respondents to inflate the small disease risks. The only previous study of preferences for meningococcal vaccination was undertaken by Bishai et al [11].…”

“…This is the first study of physician preferences for meningococcal vaccines administered to this age group and only the second study of preferences for meningococcal vaccines in general. Bishai et al [11] elicited parents' preferences and willingness to pay for meningococcal vaccines for adolescents. Similar methods have been used to quantify preferences for human papilloma virus vaccines in the United States [12] and Vietnam [13] and for vaccines against cholera and typhoid fever [14].…”

Methodological Concerns with Economic Evaluations of Meningococcal Vaccines

“…The use of a DCE by Bishai et al [45] to estimate French and German citizens' WTP across a variety of meningococcal vaccine programmes (the results of which paralleled the experience of the US market) is a promising first step towards the assessment of WTP in this area. While costbenefit analysis and WTP methodologies are not Analysis should identify threshold values of key model parameters, including the discount rate.…”

Using Conjoint Analysis to Measure the Acceptability of Rectal Microbicides Among Men Who Have Sex with Men in Four South American Cities

“…For example, patients' HIV treatment medication preferences measured by CJA successfully predicted their actual medication choices [15]. Likewise, CJA is increasingly being used to elicit consumer preferences for a wide range of medical issues, from disease treatment regimens to health care systems [15][16][17][18][19][20][21][22][23][24][25]. While actual use of a product cannot be known until the product in question actually exists, CJA can nonetheless be used to rapidly identify product attributes that may eventually affect product acceptance, and has been applied to the assessment of other developing and hypothetical biomedical HIV treatment and prevention interventions including the characteristics of Highly Active Antiretroviral Therapy (HAART) regimens in predicting adherence [26], and the acceptability of HIV vaccines [27] and PrEP [28].…”